For treating pancreatic cancer patients, which is known for having the lowest survival rate among all other common cancers, a trial has recently been initiated on its vaccination.

This trial is named as the TeloVac Trial and is supposed to be conducted at 53 UK hospitals. To become a part of this act, more than 1,000 patients suffering from advanced pancreatic cancer have joined the team. In general, vaccines are known for preventing infections, but this particular vaccination is a part of latest approach which aims to fuel up the immune system to fight against cancer.

During the trial, patients would be given regular doses of vaccine along with chemotherapy and the result of this trial would be then compared with that of chemotherapy alone.

This vaccine is made up from small sections of a protein called telomerase; this protein is over-produced by cancer cells and it targets to get converted into tumor.

In regard to this vaccination trial, Professor John Neoptolemos from Royal Liverpool University Hospital, who is helping to co-ordinate the trial, said: "The problem is tumors are clever and are able to turn the immune cells into traitors which help to guard the tumor. The vaccine takes away the masking effect of the tumor".